Genetic analysis of Indian sporadic young onset patient with Amyotrophic Lateral Sclerosis

Saileyee Roychowdhury¹, Deepika Joshi², Vinay Kumar Singh³, Mohammed Faruq⁴, Parimal Das¹

Affiliations:

1. Centre for Genetic Disorders, Institute of Science, Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India

2. Department of Neurology, Institute of Medical Sciences, Varanasi-221005, Uttar Pradesh, India

3. Centre for Bioinformatics, School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi-

221005, Uttar Pradesh, India

4. CSIR-Institute of Genomics and Integrative Biology, New Delhi, India

Correspondence: parimal@bhu.ac.in.

Abstract:

Background: Amyotrophic lateral sclerosis (ALS) is an old onset devastating neurodegenerative disorder. Youngonset ALS cases especially sporadic ones who are between 25 and 45 years are rarely affected by the disease. Despite the identification of numerous candidate genes associated with ALS, the aetiology of the disease remains elusive due to extreme genetic and phenotypic variability. The advent of affordable whole exome sequencing has opened new avenues for unraveling the disease's pathophysiology better. *Methods and Results*: Our aim was to determine the genetic basis of an Indian-origin, young onset sporadic ALS patient with very rapid deterioration of the disease course without any cognitive decline who was screened for mutations in major ALS candidate genes by Whole exome sequencing. Variants detected were reconfirmed by Sanger Sequencing. The clinicopathological features were investigated and two heterozygous missense variants harboring each in *ANXA11*, in one of the four conserved C terminal domains (R452W) and another in the *SIGMAR1* (R208W) were thus identified respectively. Both of these variants were predicted to be damaging by pathogenicity prediction tools and various *In silico* methods. *Conclusions:* Our study revealed two potentially pathogenic variants in two ALS candidate genes. The genetic makeup of ALS patients from India has been the subject of a few prior studies, but none of them examined **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. *ANXA11* and *SIGMAR1* genes so far. These results establish the framework for additional research into the

pathogenic processes behind these variations that result in sporadic ALS disease and further our understanding of the genetic makeup of Indian ALS patients.

Keywords: Amyotrophic lateral sclerosis, motor neuron disease, sporadic ALS, genetics, ANXA11 mutation, SIGMAR1 mutation

1. Introduction:

Amyotrophic lateral sclerosis is a late onset, devastating, multisystem brain neurodegenerative disorder, affecting the upper and lower motor neurons of the body. Phenotypically characterized by general weakness, muscle stiffness and spasticity, muscle atrophy, brisk reflexes, fasciculations, dysarthria, and problems in swallowing [1]. This rapid progressive disorder causes death from respiratory failure within 3-5 months of the disease onset [2], [3], [4]. Around 5-10% of cases are classed as familial ALS (fALS) cases because they have a positive family history, while the other 90-95% of cases with complex inheritance patterns are sporadic in nature (sALS) and lack a clear family history [5]. ALS has a global frequency/prevalence of 4.42 cases per 100,000 people and an annual incidence of around 1.59 cases per 100,000 people [6]. About 5-10% of ALS cases are presented with symptoms of frontotemporal dementia (FTD) and thereby falls into ALS-FTD spectrum of disease [7].

More than 30 major candidate genes have been identified to date to be linked to the disease onset [8]. The most frequently mutated are being *Sod1*, *C9orf72*, *FUS* and *TARDBP* [9]. Mutations in these genes affects major molecular pathways that lead to protein misfolding and their subsequent aggregation, impaired RNA processing, glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, and impaired axonal transport thus leading to motor neuron degeneration [10].

Recently in 2017, *ANXA11* has been included in the list of ALS causing candidate genes [11]. *ANXA11* which is ubiquitously expressed in different cell types encodes Annexin A11, which is a calcium-dependent phospholipidbinding protein [12], [13] with a molecular weight of 56 kDa and consisting of 504 amino acids [14]. It has an stabilising N terminal low complexity domain which is rich in Proline, Glycine, and tyrosine residues and are involved in liquid-liquid phase separation (LLPS) [15]. It has a binding site for a calcium-binding protein called calcyclin which is encoded by S100A6 and also for programmed cell death protein 6 encoded by PDCD6 respectively, whereas the C terminal region with 4 homologous Conserved Annexin domains of approximately 70 amino acid residues each [12], are responsible for phospholipid binding in a calcium-dependent manner and

are also involved in Ca²⁺ signalling, cell division, apoptosis, and vesicle trafficking [11], [16]. Several studies indicate that Annexins play a function in autoimmune illnesses like sarcoidosis [17],[18] cardiovascular disease [19], and cancer [20]. Recent research has found that several *ANXA11* mutations associated with ALS increase aggregation propensity, resulting in disruption of intracellular Ca2+ homeostasis and RNA granule trafficking [21].

SIGMAR1: The endoplasmic reticulum (ER) chaperone protein known as the sig-1 receptor (Sig-1R or $\sigma_1 R$) was initially identified as the sigma opioid receptor by Martin *et al.* in 1976 [22], however it was later discovered to be a unique nonopioid receptor [23]. This integral transmembrane protein encoded by *SIGMAR1*, is made up of 223 amino acids. Though expressed ubiquitously, in the neurological system, *SIGMAR1* is highly expressed in the CNS especially in the motor neurons of the brain stem and spinal cord and subcellularly enriched in postsynaptic locations [24]. This gene is involved in the regulation of various molecular functions in various cell types, including the calcium signalling, mitochondrial function, autophagy, ion channel function regulation, lipid transport and prevention of accumulation misfolded proteins [25]. Functionally $\sigma_1 R$ modulates calcium signalling via inositol 1,3,5-triphosphate receptors (IP3 receptors) [26] and binds to a variety of ligands such as neurosteroids, stimulants, and detrobenzomorphans.

During Endoplasmic Reticulum (ER) stress, $\sigma_1 R$ translocate from mitochondria-associated ER membrane (MAM), which serves as the interface between the ER and mitochondria to the plasma membrane [27]. While $\sigma_1 R$ dysfunction and its related mutations have been linked to a number of neurological diseases like Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, Distal hereditary motor neuropathies, and schizophrenia, $\sigma_1 R$ activation using ligands induces potent neuroprotective effects, improves neuronal survival, and restores neural plasticity to halt disease progression [27]–[29].

The presence of *ANXA11* and *SIGMAR1* variants have been screened in a number of cohorts from different geographic regions. While prior research has explored the genetic makeup of ALS patients in India, our study stands out by its examination of the *ANXA11* and *SIGMAR1* genes along with other ALS candidate genes, contributing to a deeper understanding of sporadic ALS and the genetic diversity within the Indian ALS patient population [30]–[32].

Young onset ALS cases have a distinct genotype and phenotypic characteristics than their older counterparts. Recent research has indicated that young-onset ALS may be more genetically predisposed than other ALS cases. SPG11, ALS2, SETX and FUS variants are the ones that are frequently altered in these cases. However, in these

cases the likelihood that other most frequently occurring genes such as *SOD1*, *TARDBP*, *C9orf72* are relatively less [33],[34],[28]. Consistent with other studies, young onset ALS cases has a spinal onset male preponderance [29], [33]. However, to fully comprehend the genetic makeup of the patients with young-onset ALS, further research is needed in future.

In this present study, we describe variations in *ANXA11* and *SIGMAR1* in a young onset ALS patient and demonstrate the impact of this mutation on the respective genes' normal function by *In silico* studies.

2. Materials and Method

2.1. Sample selection

A young male patient in early 20s (21-25 years) with a disease course of 14 months from Northern parts of India with no reported family history of neurological disorder, presented with abnormal movement of left lower limb followed by right lower limb, spasticity, speech difficulty along with atrophic hand and legs, abnormal posturing of his left hand fingers mainly, index, middle and ring fingers, weakness in the limbs and restricted movement was admitted to the neurology ward of Institute of Medical Sciences, Banaras Hindu University, India a tertiary care academic hospital in Uttar Pradesh. Initial symptoms, time of disease duration were recorded as reported by the patient and his relatives after obtaining informed written consent. The patient did not have any complaints suggesting dementia.

2.2. Clinical assessment

The proband and his mother provided information on the family history. The proband underwent electromyography (EMG) testing, nerve conduction velocity studies (NCV) of both bilateral upper and lower limbs, and magnetic resonance imaging (MRI) of his head and cervical cord. The proband also had additional laboratory testing, such as an ECG, full blood count, Ca2+ and P+, thyroid profile, vitamin B12, serum homocysteine. The neuropathological features were in accordance with the ALS El Escorial scale and was classified as a Definite ALS case as confirmed by EMG and NCV by a senior neurologist. The severity of the disease was calculated using the ALS Functional Rating Scale- Revised (ALSFRS-R). The study was conducted in accordance with the Declaration of Helsinki and the was approved by the Institutional Ethics Committee, Banaras Hindu University.

2.3. DNA isolation : Genetic analysis

Under aseptic conditions, 5 ml of peripheral blood was collected using a heparinized needle and stored in an anticoagulant (K2 EDTA) precoated collecting tube. Genomic DNA was extracted using salting out method. The quality and quantity of the DNA in the isolated sample was evaluated using Nanodrop 2000 (Thermo Fisher Scientific Inc., USA) while the integrity and quality of the sample was checked by running it on 0.8% agarose gel.

The presence of pathogenic G4C2 hexanucleotide repeat expansions in *C9orf72* was tested by Repeat-primed PCR assay along with fragment analysis [35] as well as trinucleotide CAG repeat sizes in *ATXN*-1 and *ATXN*-2 were also tested by PCR amplification by Fluorescently labelled primers [36] in the patient sample.

2.4. Next Generation Sequencing

Whole exome sequencing including all coding exons with extended UTR regions, splice sites, and extended intron regions (30bp) immediately adjacent to the alternatively spliced exons was performed by Illumina Hi-seq or Nova Seq 6000 sequencer using the Agilent V6 + UTR reagent kit (Agilent Technologies, Santa Clara, CA) with 150X2 paired end read cycles. The quality check of raw reads obtained from the next generation sequencing platform was checked using FastOC (v0.11.5) software (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). It followed removal FastX-ToolKit was by the of the adapter using (v0.0.13) (http://hannonlab.cshl.edu/fastx_toolkit/). Mapping of Paired-end raw reads to the Human Reference Genome (UCSC Genome Browser build hg19) was done using Bowtie2 software (v2.2.6) (http://bowtiebio.sourceforge.net/bowtie2/index.shtml) followed by the variant calling and annotation, performed by using (https://gatk.broadinstitute.org/hc/en-us) GATK (v3.4.46) and **SnpEff** (v4.3) (http://snpeff.sourceforge.net/SnpEff_manual.html) or Annovar (v24/10/2019) (https://docopenbio.readthedocs.io/projects/annovar/en/latest/), respectively. Variants were classified and interpreted according to American College of Medical Genetics and Genomics (ACMG) guidelines.

For identifying the genes responsible for disease occurrence, variants were further selected from the annotated VCF file following these criteria: read depth of at least 30×, Minor allele frequency (MAF) < 1% in several population databases like Genome Aggregation Database (GnomAD) (<u>https://gnomad.broadinstitute.org/</u>) [37], ExAC (<u>http://exac.broadinstitute.org/</u>), 1000genome database (<u>https://www.internationalgenome.org/</u>), Human gene mutation database (HGMD) (<u>https://www.hgmd.cf.ac.uk</u>) , database of single nucleotide polymorphism (dbSNP) (<u>http://www.ncbi.nlm.nih.gov/projects/SNP</u>), Exome variant server (<u>https://evs.gs.washington.edu</u>).

Pathogenicity prediction: The plausible effects of the identified variants found were determined initially through available online *In silico* tools such as SIFT [38], PolyPhen-2 [39], Mutation taster [40], SNPs&GO [41] and PROVEAN [42] respectively. Variants that were non synonymous in nature and classified as pathogenic, likely pathogenic and variants of uncertain significance (VUS), were only considered for the study.

2.5. Sanger sequencing

Primers were designed for exon containing specific mutations for Polymerase chain reaction (Thermal cycler, ABI). After PCR amplification the amplified product was purified by Exonuclease and Shrimp Alkaline Phosphatase (USB Affymetrix, USA) and directly sequenced on an ABI 3130 automated sequencer (Applied Biosystems, CA, USA) for reconfirmation of the proband's DNA sequence variants found through NGS. Sequencing reads were then compared against NCBI BLAST.

2.6. Evolutionary conservation analysis

For the ANXA11 and SIGMAR1 proteins, the evolutionary conservation of amnio acid residues was evaluated using the CONSURF algorithm. The homology search algorithm used was HMMER in 1 iteration with cut off of 0.0001 for the E-value. The protein database of choice was UNIPROT. For homologs, 95% and 35% were chosen as the maximum and minimum identities, respectively. The Multiple Sequence Alignment (MSA) was built using CLUSTALW as the alignment method. The scores were calculated according to Bayesian method.

2.7. Secondary structure prediction

For protein structure prediction, the PSIPRED programme (<u>http://bioinf.cs.ucl.ac.uk/psipred/</u>) was used which combines PSIPRED, GenTHREADER, and MEMSAT2 techniques. Two feed-forward neural networks are used in this prediction method to analyse the results of PSI-BLAST [43]. While the second network forecasts interactions between proteins and ligands, the first network detects residues that are crucial for defining a ligand's position [43].

2.8. Homology modelling prediction:

Since hANXA11 did not have a crystal structure, homology modelling using computational method was used to determine its three-dimensional (3D) structure along with R452W variant, using the I-TASSER [44], RaptorX [45] and LOMET programs. Through adjusting the protein sequence and interaction partners, a total of 5 models were produced. On the basis of the R-factor and Ramachandran plot, the model that best fit the experimental data was selected. In case of Sigmar1 variant its wild type structure was retrieved from PDB. Then 3D structure of

R208W variant was predicted through homology modelling using I-Tasser. Structure refinement of the predicted model was done using ModRefiner [46]. SAVES v6.0 toolkit (https://saves.mbi.ucla.edu/) [47] comprising of 5 tools namely ERRAT, VERIFY3D, PROVE, PROCHECK and WHATCHECK was used to further validate the predicted models. This toolkit predicts several stereochemical properties of the protein structure by evaluating the Ramachandran plot or by using PROCHECK to analyze the geometry of the entire model as well as the geometry of each individual residue. In order to compare the 3D structural differences between the wild type and the variant type, the models were then visualized and superimposed using Biovia Discovery Studio Visualizer.

2.9. Molecular dynamics simulation studies

In order to identify the pathogenicity of the variants found, Molecular dynamics (MD) studies were performed on the wild type and the mutated type of *ANXA11* and *SIGMAR1* respectively. The models of wild type and its variant of both *ANXA11* and *SIGMAR1* were submitted to online WebGRO Macromolecular Simulations server (<u>https://simlab.uams.edu/</u>). The models were simulated for 100 ns by implying GROMOS96 43a1 forcefield and the protein fragment was solvated in SPS water molecules in a triclinic box and sodium chloride, neutralized and 0.15M salt of NaCl was introduced. Using the steepest descent method for every 5000 steps, the systems underwent energy minimization. The NVT/NPT equilibration was carried out at 300 K and 1 bar of pressure. The MD integrator used was Leap-frog with simulation time of 100ns and the number of frames per simulation were fixed at 1000 [48]. Main parameters such as RMSD (Root Mean Square Deviation), RMSF (Root Mean Square Fluctuation), were evaluated for complexes stability.

2.10. Prediction of change in stability due to variation in protein sequence

I-Mutant 2.0 (<u>https://folding.biofold.org/i-mutant/i-mutant2.0.html</u>), a support vector machine tool, was used to predict how the protein's stability would change after a mutation. The I-Mutant 2.0 server, which automatically predicts changes in protein stability caused by single point mutations, was developed and tested using the most comprehensive thermodynamic experimental data library of free energy changes in protein stability due to mutation, ProTherm. I Mutant 2.0 can be used as a regression estimator by predicting the change in Gibbs-free energy (G) due to a point mutation, as well as a classifier for determining the direction of the change in protein stability [49].

3. RESULTS

3.1. Clinical assessment

The young male patient with complaints of weakness of all four limbs and difficulty in speech for last 14 months was admitted. The patient had the limb as the first place of disease onset. The patient, who was a nonsmoker and non alcoholic was apparently alright fourteen months back from the time of admission when he first developed weakness of left lower limb in the form of slipping of his slippers from his foot with awareness but could perform his daily activities. He had insidious onset of symptoms which slowly became progressive after few months. He gradually had weakness of left upper limb with difficulty in holding small objects. The symptoms gradually progressed to right lower limb and then to right upper limb whereby he performing any of his daily activities became challenging. It was progressed further to bulbar regions with speech difficulty and swallowing problems. The patient also complained of increased stiffness of his upper and lower limbs. There was a marked atrophy of the muscles of his hands and legs. There was no history of any numbness or tingling sensation or any history of burning sensation over the body.

On history of clinical examination, the patient was found to have gradually progressive spastic asymmetric quadriparesis, upper motor neuron (UMN) type with UMN type speech with pseudobulbar effect with visible fasciculations over tongue and upper limbs without any sensory or cranial involvement with normal bowel and bladder. NCV and EMG studies confirmed the case to be a definite young onset ALS (UMN and LMN quadriparesis). ALSFR score measured was 21 out of 40.

3.2. Genetic results

Two heterozygous missense variation, one located in exon 16 of *ANXA11* (c.1354>T) altering the amino acid at 452 position from Arginine to Tryptophan (p.R452W) and the other missense variant (c.622C>T, p.R208W, rs11559048) altering the amino acid at 208 position from Arginine to Tryptophan in exon 4 of the *SIGMAR1* respectively were identified in the young onset ALS patient sample. In both the cases, a hydrophilic and basic amnio acid, Arginine got converted into a hydrophobic and aliphatic amino acid, Tryptophan. The *ANXA11* variant (p.R452W) was present in one of the conserved homologous domains in the C terminal region. It has been found that patients with variations in the conserved ANX domain suffer from more classical phenotypes than the bulbar onset [50], which was also seen in our patient. No other variants were found in other ALS candidate genes. The Minor Allele Frequency (MAF) of *ANXA11* p.R452W is <0.01 while the p.R208W in *SIGMAR1* has a MAF of 0.007 (global) and 0.019 (South Asian) according to ExAC database respectively. The Phred-scaled Combined

Annotation Dependent Depletion (CADD) score for both the variants were > 30. Both the variations were cross confirmed by Sanger Sequencing (Fig 2a, 2b).

3.3. Pathogenicity prediction

Several different *In silico* pathogenicity prediction algorithms such as Mutation Taster, SIFT [38], Polyphen and PROVEAN that were used to predict the functional and structural effects of these variants at the protein level, predicted both R452W and R208W to be deleterious in nature as shown in Table 1.

Table1: Pathogenicity prediction of ANXA11 R452W and SIGMAR1 R208W variants by different In silico tools

Pathogenic Prediction tools	ANXA11 p.R452W	SIGMAR1 p.R208W
SIFT	Deleterious	Deleterious
PROVEAN	Deleterious	Deleterious
PolyPhen	Deleterious	Deleterious
Mutation Taster	Deleterious	Deleterious
LRT	Neutral	Deleterious
SNPs&GO	Deleterious	Deleterious

3.4. Conservation analysis

Consurf analysis showed that though the R452W variant in *ANXA11* is present in one of the four conserved domains in the C terminal region, however the amino acid Arginine (R) with a conservation score of 2 out of 10 is predicted to be variable in nature (Fig: 3a). The R208W variant had a score of 5 out of 10 denoting that it is averagely conserved across species. (Fig: 3b), therefore any mutation at that position might hamper its function as well.

3.5. Bioinformatic analysis

Secondary structure prediction: Analysis of the secondary structure by PsiPred showed significant sites of alterations both at upstream and downstream positions from the site of variation in the mutated R452W ANXA11.

These changes included shortening of a helical structure (431- 432 aa and 451-457 aa)) and increase in the strand structure (458-460) (Fig:4) whereas a slight change was found in case of mutated R208W *SIGMAR1* variant. (Fig:5)

3.6. Prediction of Protein stability

Using the software, I-Mutant 2.0, it was found that there was a decrease in stability of the amino acid substitution from Arginine to Tryptophan at 452 position in *ANXA11* gene ($\Delta\Delta G$ = -0.77) and 208 position in SIGMAR1 gene ($\Delta\Delta G$ = -0.37) respectively at pH 7.0 and temperature 25C.

3.7. Physiochemical properties

The characteristics of individual amino acid that constitute a protein are greatly influenced by their physiochemical properties. Since, every change in an amino acid at a given position has the potential to affect the physiochemical properties of that respective protein, our next goal was to investigate how the R452W and R208W mutations affected the overall physiochemical characteristics of wild ANXA11 and SIGMAR1 respectively. Therefore, Protscale software was used which predicted the mutant p. R452W to have lower hydropathicity (Fig: 6a and 6b), increased hydrophobicity (Fig: 6c and 6d), decrease in polarity (Fig: 6e and 6f) and slight increase in alpha helix structure (Fig: 6G and 6H) when compared to ANXA11 wild type within the region of amino acid substitution whereas p.R208W was found to have increased hydropathicity and hydrophobicity, lower polarity and slight increase in the alpha helix structure when compared to the wild type SIGMAR1 (Fig: 7a-7f). In spite of having one amino acid substitution in the protein structure, the overall molecular weight increased in both p.R452W and p.R208W variant types when compared to their wild types. Instability index showed that both SIGMAR1 wild type and p.R208W variant are stable in nature (instability index<40) while both wild type ANXA11 and its variant p.R452W are instable in nature (instability index >55). Aliphatic index (AI) refers to the proportion of a protein's volume that is occupied by its aliphatic side chains which in return influences the thermal stability of proteins. Proteins are more thermally stable and tend to have an increased hydrophobicity when their aliphatic index is high. Though the aliphatic index was same in both the cases when compared to their wild counterparts however the very high aliphatic index of SIGMAR1 and its mutated type p.R208W indicates that they might be thermally stable over a wide range of temperature. There was a slight increase in the Grand average of hydropathicity (GRAVY) value which measures the sum of hydropathy values for all amino acids divided by the length of the sequence, in p.R452W with respect to ANXA11 wild type, though both of them are slightly hydrophilic intrinsically in nature with negative GRAVY value indicating that the surface accessibility of the mutated protein

might be affected, whereas *SIGMAR1* and R208W are slightly hydrophobic in nature. The isoelectric point (Theoretical pI) of R452W (6.91) indicated that it has become more acidic from basic than its wild type with theoretical pI measuring 7.53 while R208W of *SIGMAR1* has become slightly acidic when compared to its wild type (Table 2.).

Physiochemical Properties	ANXA11 wild	ANXA11 R452W	SIGMAR1 wild	SIGMAR1 R208W
Molecular weight	54389.71	54419.74	25127.69	25157.72
Insatbility index	58.66	58.51	34.02	33.94
Aliphatic index	64.97	64.97	94.48	94.48
Grand average of hydropathicity	- 0.521	-0.514	0.134	0.150
(GRAVY)				
Theoretical pI	7.53	6.91	5.61	5.45

Table 2: Differences in physiochemical properties of wild type and its variant of ANXA11 and SIGMAR1

3.8. Homology modelling

The three-dimensional protein structure of both the wild type *ANXA11* and *SIGMAR1* and its variant p.R452W and p.R208W were modelled and validated. PROCHECK Ramachandran plot analysis of both the wild and mutated type of *ANXA11* and *SIGMAR1* showed that most of the amino acids are in favoured and allowed regions (Fig: 8). Moreover, the superimposed structure of p.R452W and p.R208W with their wild types further showed changes in three-dimensional structure due to the variation (Fig: 9).

3.9. Molecular Dynamics simulation result:

The data from the modelled superimposed structure were further supported by molecular dynamics simulation studies. Root mean square deviation is a commonly used indicator of structural separation between coordinates. It calculates the typical separation between a collection of atoms (backbone atoms of a protein). The RMSD value of two sets of protein structures (wild type and variant type) thereby indicates how much the protein shape has

changed at two time points from the trajectory. Root mean square Fluctuation measures a particle's average deviation from a reference point over time. Thus, RMSF analyses the structural elements that deviate most from their mean (or least).

Between the aligned structures of the wild type and its variation in *ANXA11* and *SIGMAR1* respectively, the RMSD and RMSF values demonstrate a considerable difference as depicted in Fig (10-13).

4. **DISCUSSION:**

The high degree of clinical and genetic variability among different ALS patients along with the absence of any biological markers makes the diagnosis extremely difficult. *SOD1 FUS*, *TDP43* and *C9orf72* are the most frequently implicated genes in around two thirds of familial ALS cases. Since the majority of these genes are often inherited in an autosomal dominant manner, sporadic occurrence is extremely unlikely to be caused by them.

However, genes such as *SPG11*, *ALS2*, *SETX* and *FUS* have been linked to the rare forms of young onset ALS cases [33], [34], [51]. *ANXA11* and *SIGMAR1* have been recently identified as ALS candidate gene and several disease-causing mutations have been identified in these genes so far [24], [52]. Previous studies have delved in to the genetic composition of ALS patients in India but mutations in *ANXA11* and *SIGMAR1* has not been screened in Indian population so far. Our study distinguishes itself by screening not only previously reported candidate genes in India but also screening *ANXA11* and *SIGMAR1along with* other major ALS candidate genes

In the present study, Next generation sequencing identified a missense, non-synonymous variant in one of the conserved Annexin domain located in exon 16 of *ANXA11* along with another nonsynonymous variant in *SIGMAR1* in an aggressive young onset ALS patient with negative cognitive impairment. No other variants were found in other ALS candidate genes including pathogenic and intermediate repeat expansions in *C9orf72*, *ATXN1* and *ATXN2*, respectively.

Previous studies have found that mutations in *ANXA11* causes dysregulation of calcium homeostasis and stress granule dynamics [16]. Ca2+ homeostasis and SG dynamics are two vital physiological processes that are becoming more and more important in ALS research, and *ANXA11* is a key link between them. C terminal region of *ANXA11* with 4 homologous Conserved Annexin domains, are responsible for phospholipid binding in a calcium-dependent manner and are involved in Ca²⁺ signaling, cell division, apoptosis, and vesicle trafficking [11], [21], *ANXA11* gene mutations can cause abnormal protein aggregation and motor neuron mortality by

upsetting the intracellular Ca2+ equilibrium [16]. Both motor neurons and skeletal muscle fibres are susceptible to protein misfolding caused by the *ANXA11* missense mutation [53].

SIGMAR1 is an endoplasmic reticulum protein that regulates variety of molecular functions in various cell types, including the calcium signalling via inositol 1,3,5-triphosphate receptors (IP3 receptors) [26], mitochondrial function, autophagy, ion channel function regulation, lipid transport and prevention of accumulation misfolded proteins [25]. The motor neurons in the brainstem and spinal cord exhibit significant expression of this gene. Several studies have shown an association of several distal neuropathies with severe skeletal muscle dysfuction such as involvement of motor neurons, muscle wasting and atrophy to be linked with mutations in the *SIGMAR1* gene.

Majority of the In silico pathogenicity prediction tools like Mutation Taster, Polyphen and SIFT, PROVEAN and SNP&Go predicted these variants to be associated with the disease and highly deleterious in nature. The missense variant of ANXA11; p.R452W, has not been associated with ALS till date, to the best of our knowledge. The p.R208W in SIGMAR1 with a MAF of 0.007 (Global) and 0.019 (South Asian population) respectively and has been previously identified in an old onset Japanese ALS patient [54]. When we analysed and compared the physiochemical properties (hydropathicity, hydrophobicity, molecular weight, polarity, alpha helix, isoelectric point) of the mutated proteins p. R452W and p.R208W respectively vs. the wild type ANXA11 and SIGMAR1 respectively, significant changes were found in both p.R452W and p.R208W variants. Further secondary structure prediction especially in case of mutant p.R452W of ANXA11 showed significant changes in the confirmation. Superimposition of the wild and mutated type of the protein also revealed that both of the mutants vary considerably from their wild type which is further substantiated by the RMSD and RMSF plots obtained from molecular dynamics simulation results. In silico studies predicted that there is significant change in the mutated protein structure compared to its wild type which might result in altered protein function therefore having effect on disease onset and progression. Hence, based on all these results we predicted that the missense variants found in our study are likely pathogenic and have a relationship with the development of disease. Multiple genetic variants may interact among themselves simultaneously to increase risk of ALS, therefore the possibility that both R452W and R208W variant has contributed to the disease pathogenicity can't be ruled out. Therefore, it is necessary to screen ANXA11 and SIGMAR1 in large sample size of young onset ALS patients of Indian origin to determine its frequency in the affected population. Further studies need to be conducted to identify the functional implications of these mutations in ALS patients.

5. Conclusion

Our findings broaden the spectrum of ALS causing genes in Indian ALS patients and necessitates neurologists to screen for mutations in *ANXA11* and *SIGMAR1* genes in young onset ALS as well. As ALS is a late onset neurodegenerative disorder where both the genetic mutations accumulating over the years and the environmental factors trigger and predispose the patient towards disease onset, it is important to screen and identify the underlying genetic background of relatively young onset ALS cases where chances of frequency of known ALS candidate gene mutations becomes very high. Moreover, the discovery of a disease-causing gene mutation may eventually result in treatment in the form of personalized medicine in the future.

Statement and Declarations:

Ethics declaration: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Institute of Science, Banaras Hindu University (*Ref No: I.Sc/ECM-XIV/2022-23/*)

Conflict of Interest: The authors declare that there is no conflict of interest regarding publication of this article.

Acknowledgement: The authors are grateful to the patient and his family members for their contribution to this study. The authors wish to thank Ms. Pooja Sharma, Research Scholar, CSIR- IGIB, New Delhi, India for providing help with the repeat expansion work.

The first author acknowledges Department of Science and Technology (DST), India for providing Junior Research Fellowship (JRF) & Senior Research Fellowship (SRF).

References:

- [1] V. Pecoraro, J. Mandrioli, C. Carone, A. Chiò, B. J. Traynor, and T. Trenti, "The NGS technology for the identification of genes associated with the ALS. A systematic review," *Eur. J. Clin. Invest.*, vol. 50, no. 5, p. e13228, May 2020, doi: 10.1111/ECI.13228.
- H. F. Li and Z. Y. Wu, "Genotype-phenotype correlations of amyotrophic lateral sclerosis," *Transl. Neurodegener.*, vol. 5, no. 1, pp. 1–10, 2016, doi: 10.1186/s40035-016-0050-8.
- [3] R. H. Brown and A. Al-Chalabi, "Amyotrophic Lateral Sclerosis," *N. Engl. J. Med.*, vol. 377, no. 2, pp. 162–172, Jul. 2017, doi: 10.1056/NEJMra1603471.
- [4] K. Del Tredici and A. Ludolph, "The multisystem degeneration amyotrophic lateral sclerosisneuropathological staging and clinical translation," doi: 10.12871/00039829201746.
- [5] A. Nishiyama, T. Niihori, H. Warita, ... R. I.-N. of, and undefined 2017, "Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis," *Elsevier*.
- [6] L. Xu *et al.*, "Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis," *J. Neurol.*, vol. 267, no. 4, pp. 944–953, Apr. 2020, doi: 10.1007/s00415-019-09652-y.
- Y. A. Abramzon, P. Fratta, B. J. Traynor, and R. Chia, "The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia," *Front. Neurosci.*, vol. 14, p. 42, Feb. 2020, doi: 10.3389/FNINS.2020.00042/BIBTEX.
- [8] C. Maurel *et al.*, "Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration," *Mol. Neurobiol.*, vol. 55, no. 8, pp. 6480–6499, Aug. 2018, doi: 10.1007/S12035-017-0856-0.
- [9] S. Mathis, C. Goizet, A. Soulages, J. M. Vallat, and G. Le Masson, "Genetics of amyotrophic lateral sclerosis: A review," J. Neurol. Sci., vol. 399, pp. 217–226, Apr. 2019, doi: 10.1016/J.JNS.2019.02.030.
- J. M. Gregory, D. Fagegaltier, H. Phatnani, and M. B. Harms, "Genetics of Amyotrophic Lateral Sclerosis," *Curr. Genet. Med. Rep.*, vol. 8, no. 6, pp. 121–131, 2020, doi: 10.1007/S40142-020-00194-8.
- [11] S. D. Topp *et al.*, "Mutations in the vesicular trafficking protein Annexin A11 are associated with amyotrophic lateral sclerosis Bradley N. Smith," *Sci. Transl. Med.*, vol. 9, no. 388, May 2017, doi:

10.1126/SCITRANSLMED.AAD9157/SUPPL_FILE/AAD9157_TABLES_S1_TO_S7.ZIP.

- [12] S. E. Moss and R. O. Morgan, "The annexins," *Genome Biol.*, vol. 5, no. 4, pp. 1–8, Mar. 2004, doi: 10.1186/GB-2004-5-4-219/FIGURES/4.
- [13] J. Wang *et al.*, "Annexin A11 in disease," *Clin. Chim. Acta*, vol. 431, pp. 164–168, Apr. 2014, doi: 10.1016/J.CCA.2014.01.031.
- [14] Y. Misaki, G. J. M. Pruijn, A. W. C. M. Van Der Kemp, and W. J. Van Venrooij, "The 56K autoantigen is identical to human annexin XI.," *J. Biol. Chem.*, vol. 269, no. 6, pp. 4240–4246, Feb. 1994, doi: 10.1016/S0021-9258(17)41769-8.
- P. A. G. Lillebostad *et al.*, "Structure of the ALS Mutation Target Annexin A11 Reveals a Stabilising N-Terminal Segment," *Biomol. 2020, Vol. 10, Page 660*, vol. 10, no. 4, p. 660, Apr. 2020, doi: 10.3390/BIOM10040660.
- [16] M. Nahm *et al.*, "ANXA11 mutations in ALS cause dysregulation of calcium homeostasis and stress granule dynamics," *Sci. Transl. Med.*, vol. 12, no. 566, Oct. 2020, doi: 10.1126/SCITRANSLMED.AAX3993/SUPPL_FILE/AAX3993_SM.PDF.
- [17] S. Hofmann *et al.*, "Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis," *Nat. Genet. 2008 409*, vol. 40, no. 9, pp. 1103–1106, Aug. 2008, doi: 10.1038/ng.198.
- Y. Li, S. Pabst, C. Kubisch, C. Grohé, and B. Wollnik, "First independent replication study confirms the strong genetic association of ANXA11 with sarcoidosis," *Thorax*, vol. 65, no. 10, pp. 939–940, Oct. 2010, doi: 10.1136/THX.2010.138743.
- S. Sen-Chowdhry, P. Syrris, and W. J. McKenna, "Genetics of restrictive cardiomyopathy.," *Heart Fail. Clin.*, vol. 6, no. 2, pp. 179–186, Apr. 2010, doi: 10.1016/J.HFC.2009.11.005.
- [20] Y. J. Jiao *et al.*, "Characterization and proteomic profiling of pancreatic cancer-derived serum exosomes," *J. Cell. Biochem.*, vol. 120, no. 1, pp. 988–999, Jan. 2019, doi: 10.1002/JCB.27465.
- Y. C. Liao *et al.*, "RNA Granules Hitchhike on Lysosomes for Long-Distance Transport, Using Annexin A11 as a Molecular Tether," *Cell*, vol. 179, no. 1, pp. 147-164.e20, Sep. 2019, doi: 10.1016/J.CELL.2019.08.050.
- [22] W. R. Martin, C. G. Eades, J. A. Thompson, R. E. Huppler, and P. E. Gilbert, "The effects of morphine-

and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.," *J. Pharmacol. Exp. Ther.*, vol. 197, no. 3, 1976.

- [23] T. Hayashi and T. P. Su, "σ-1 receptor ligands: Potential in the treatment of neuropsychiatric disorders,"
 CNS Drugs, vol. 18, no. 5, pp. 269–284, 2004, doi: 10.2165/00023210-200418050-00001.
- [24] A. Al-Saif, F. Al-Mohanna, and S. Bohlega, "A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis," *Ann. Neurol.*, vol. 70, no. 6, pp. 913–919, Dec. 2011, doi: 10.1002/ANA.22534.
- [25] R. Aishwarya, C. S. Abdullah, M. Morshed, N. S. Remex, and M. S. Bhuiyan, "Sigmar1's Molecular, Cellular, and Biological Functions in Regulating Cellular Pathophysiology," *Front. Physiol.*, vol. 12, Jul. 2021, doi: 10.3389/FPHYS.2021.705575.
- [26] T. Hayashi and T. P. Su, "Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival," *Cell*, vol. 131, no. 3, pp. 596–610, Nov. 2007, doi: 10.1016/J.CELL.2007.08.036.
- [27] E. E. Benarroch, "Sigma-1 receptor and amyotrophic lateral sclerosis," *Neurology*, vol. 91, no. 16, pp. 743–747, Oct. 2018, doi: 10.1212/WNL.00000000006347.
- [28] J. Deng *et al.*, "Novel and Recurrent Mutations in a Cohort of Chinese Patients With Young-Onset Amyotrophic Lateral Sclerosis," *Front. Neurosci.*, vol. 13, p. 1289, Dec. 2019, doi: 10.3389/FNINS.2019.01289/BIBTEX.
- [29] B. Swinnen and W. Robberecht, "The phenotypic variability of amyotrophic lateral sclerosis," *Nat. Rev. Neurol. 2014 1011*, vol. 10, no. 11, pp. 661–670, Oct. 2014, doi: 10.1038/nrneurol.2014.184.
- [30] A. Vats *et al.*, "Analysis of C9orf72 repeat expansion in amyotrophic lateral sclerosis patients from North India," *J. Neurol. Sci.*, vol. 373, pp. 55–57, Feb. 2017, doi: 10.1016/J.JNS.2016.11.079.
- [31] P. Narain, J. Gomes, R. Bhatia, I. Singh, and P. Vivekanandan, "C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis," *Neurobiol. Aging*, vol. 56, pp. 211.e9-211.e14, Aug. 2017, doi: 10.1016/J.NEUROBIOLAGING.2017.04.011.
- [32] P. Narain, A. Pandey, S. Gupta, J. Gomes, R. Bhatia, and P. Vivekanandan, "Targeted next-generation

sequencing reveals novel and rare variants in Indian patients with amyotrophic lateral sclerosis," *Neurobiol. Aging*, vol. 71, pp. 265.e9-265.e14, 2018, doi: 10.1016/j.neurobiolaging.2018.05.012.

- [33] J. Lin, W. Chen, P. Huang, Y. Xie, M. Zheng, and X. Yao, "The distinct manifestation of young-onset amyotrophic lateral sclerosis in China," *https://doi.org/10.1080/21678421.2020.1797091*, vol. 22, no. 1–2, pp. 30–37, 2020, doi: 10.1080/21678421.2020.1797091.
- [34] M. Gromicho, M. Oliveira Santos, A. Pinto, A. Pronto-Laborinho, and M. De Carvalho, "Young-onset rapidly progressive ALS associated with heterozygous FUS mutation," https://doi.org/10.1080/21678421.2017.1299762, vol. 18, no. 5–6, pp. 451–453, Jul. 2017, doi: 10.1080/21678421.2017.1299762.
- [35] U. Shamim *et al.*, "C9orf72 Hexanucleotide repeat expansion in Indian ALS patients: A common founder and its geographical predilection.," *Neurobiol. Aging*, 2019, doi: 10.1016/j.neurobiolaging.2019.12.024.
- [36] P. Sharma *et al.*, "Genetics of Ataxias in Indian Population: A Collative Insight from a Common Genetic Screening Tool," *Adv. Genet.*, vol. 3, no. 2, p. 2100078, Jun. 2022, doi: 10.1002/GGN2.202100078.
- [37] A. Bartoletti-Stella *et al.*, "Targeted sequencing panels in Italian ALS patients support different etiologies in the ALS/FTD continuum," *J. Neurol.*, vol. 268, no. 10, pp. 3766–3776, Oct. 2021, doi: 10.1007/S00415-021-10521-W.
- [38] P. Ng, S. H.-N. acids research, and undefined 2003, "SIFT: Predicting amino acid changes that affect protein function," *academic.oup.com*.
- [39] I. A. Adzhubei *et al.*, "A method and server for predicting damaging missense mutations," *Nat. Methods* 2010 74, vol. 7, no. 4, pp. 248–249, Apr. 2010, doi: 10.1038/nmeth0410-248.
- [40] J. M. Schwarz, D. N. Cooper, M. Schuelke, and D. Seelow, "MutationTaster2: mutation prediction for the deep-sequencing age," *Nat. Methods 2014 114*, vol. 11, no. 4, pp. 361–362, Mar. 2014, doi: 10.1038/nmeth.2890.
- [41] E. Capriotti, R. Calabrese, P. Fariselli, P. L. Martelli, R. B. Altman, and R. Casadio, "WS-SNPs&GO: a web server for predicting the deleterious effect of human protein variants using functional annotation.,"

BMC Genomics, vol. 14 Suppl 3, no. 3, pp. 1–7, May 2013, doi: 10.1186/1471-2164-14-S3-S6/FIGURES/2.

- [42] Y. Choi and A. P. Chan, "PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels," *Bioinformatics*, vol. 31, no. 16, p. 2745, Aug. 2015, doi: 10.1093/BIOINFORMATICS/BTV195.
- [43] D. W. A. Buchan, F. Minneci, T. C. O. Nugent, K. Bryson, and D. T. Jones, "Scalable web services for the PSIPRED Protein Analysis Workbench," *Nucleic Acids Res.*, vol. 41, no. W1, pp. W349–W357, Jul. 2013, doi: 10.1093/NAR/GKT381.
- [44] J. Yang *et al.*, "The I-TASSER Suite: protein structure and function prediction," *nature.com*.
- [45] M. Källberg *et al.*, "Template-based protein structure modeling using the RaptorX web server," *nature.com.*
- [46] D. Xu and Y. Zhang, "Improving the Physical Realism and Structural Accuracy of Protein Models by a Two-Step Atomic-Level Energy Minimization," *Biophys. J.*, vol. 101, no. 10, pp. 2525–2534, Nov. 2011, doi: 10.1016/J.BPJ.2011.10.024.
- [47] C. Colovos and T. O. Yeates, "Verification of protein structures: Patterns of nonbonded atomic interactions," *Protein Sci.*, vol. 2, no. 9, pp. 1511–1519, Sep. 1993, doi: 10.1002/PRO.5560020916.
- [48] T. Ongtanasup, A. Mazumder, A. Dwivedi, and K. Eawsakul, "Homology Modeling, Molecular Docking, Molecular Dynamic Simulation, and Drug-Likeness of the Modified Alpha-Mangostin against the β-Tubulin Protein of Acanthamoeba Keratitis," *Molecules*, vol. 27, no. 19, Oct. 2022, doi: 10.3390/MOLECULES27196338.
- [49] E. Capriotti, P. Fariselli, and R. Casadio, "I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure," *Nucleic Acids Res.*, vol. 33, no. suppl_2, pp. W306–W310, Jul. 2005, doi: 10.1093/NAR/GKI375.
- [50] W. Sung *et al.*, "Clinical and genetic characteristics of amyotrophic lateral sclerosis patients with ANXA11 variants," *Brain Commun.*, vol. 4, no. 6, Nov. 2022, doi: 10.1093/BRAINCOMMS/FCAC299.
- [51] A. K. Artemiadis, C. Peppas, S. Giannopoulos, V. Zouvelou, and N. Triantafyllou, "Case of Young-

Onset Sporadic Amyotrophic Lateral Sclerosis," J. Clin. Neuromuscul. Dis., vol. 17, no. 4, pp. 220–222, Jun. 2016, doi: 10.1097/CND.00000000000107.

- [52] E. Teyssou *et al.*, "Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis," *Neurobiol. Aging*, vol. 99, pp. 102.e11-102.e20, Mar. 2021, doi: 10.1016/J.NEUROBIOLAGING.2020.10.015.
- [53] K. Zhang *et al.*, "ANXA11 mutations prevail in Chinese ALS patients with and without cognitive dementia," *Neurol. Genet.*, vol. 4, no. 3, p. 237, Jun. 2018, doi: 10.1212/NXG.0000000000237.
- [54] Y. Izumi, H. Morino, R. Miyamoto, and Y. Matsuda, "Compound heterozygote mutations in the SIGMAR1 gene in an oldest-old patient with amyotrophic lateral sclerosis," *Artic. Geriatr. Gerontol. Int.*, 2018, doi: 10.1111/ggi.13506.

Author contributions:

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Saileyee Roychowdhury, Deepika Joshi, Vinay K Singh, Mohammed Faruq and Parimal Das. The first draft of the manuscript was written by Saileyee Roychowdhury and was checked by Parimal Das. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data Availability

All data generated or analysed during this study are included in this published article.



b. SIGMAR1 protein structure

Fig:1 Graphical representation of (a) the domains present in the ANXA11 protein. LCD represents low complexity domain which is a binding site for another calcium-binding protein, Calcyclin.in the extended N terminal region. Annexin 1 Annexin 2, Annexin 3, Annexin 4 represents conserved homologous domains associated with phospholipid binding via calcium regulation in the in the C terminal region. The Red arrow indicate the position of p.R452W mutation (b) the exons with the number of amino acids respectively and introns present in the SIGMAR1 protein. The red arrow indicates the position of p.R208W mutation



Fig: 2 Chromatograms showing changes in (a) ANXA11 c.1354C>T change (p.R452W) and (b) SIGMAR1 c.622C>T (p.R208W)



Fig: 3a Conservational analysis of ANXA11 wild. Conservation score= 2



41

GAVCLLTA

191

Conservation score= 5



a.

Fig:4 (a) Site of alterations shown in circle in the predicted secondary structure of a. ANXA11 wild type (b) ANX11 R452W type by PSIPRED



Fig: 5 (a) Predicted secondary structure of a. SIGMAR1 wild type (b) SIGMAR1 R208W type by PSIPRED



Fig: 6 Physiochemical properties of ANXA11 wild vs R452W variant. (a,b) denotes lower hydropathicity of R452W compared to its wild type (c,d) denotes increased hydrophobicity of R452W compared to its wild type (e,f) denotes lower polarity of R452W compared to its wild type (g,h) denotes slight increase in alpha helix of R452W compared to its wild type. The x-axis represents the position of the amino acids while the y-axis represents the score in a default window size of 9



Fig 7: Physiochemical properties of SIGMAR1 wild vs R208W variant. (a,b) denotes increased hydropathicity of R208W compared to its wild type. (c,d) denotes increased hydrophobicity of R208W compared to its wild type. (e,f) denotes lower polarity of R208W compared to its wild type. (g,h) denotes slight increase in alpha helix of R208W compared to its wild type. The x-axis represents the position of the amino acids while the y-axis represents the score in a default window size of 9



Fig: 8 (a) Ramachandran plot of (a) ANXA11 R452W model and (b) SIGMAR1 R208W model



Fig: 9 Superimposed structure of wild and variant type of (a) ANXA11 and (b) SIGMAR. Blue denotes the wild type while Red denotes the mutated variant



Fig:10 RMSD analysis of wild type ANXA11 and its variant (R452W) over time (ns)



Fig:11 RMSF analysis of wild type ANXA11 and its variant (R452W)



Fig:12 RMSD analysis of wild type SIGMAR1 and its variant (R208W) over time (ns)



Fig:13 RMSF analysis of wild type SIGMAR1 and its variant (R208W)